LLY vs SAVA

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Cassava Sciences continues to face an existential crisis due to unresolved allegations of data manipulation and ongoing regulatory investigations by the FDA and NIH concerning its lead drug candidate, simufilam. While the Alzheimer's market offers theoretical 10x growth potential, this is fundamentally undermined by a profound trust deficit in leadership and the scientific integrity of their core ...